SCHEMBL711564

SCHEMBL711564

O=S(=O)(Nc1nccs1)c1ccc(Nc2nc3ccccc3o2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.55
KDR P35968 1/20 0.55
PIK3R1 P27986 1/20 0.54
PIK3CA P42336 1/20 0.54
MTOR P42345 1/20 0.54
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
POLB P06746 2/20 0.53
CASP6 P55212 1/20 0.53
ALDH1A1 P00352 4/20 0.53
PKM P14618 3/20 0.53
ATM Q13315 1/20 0.53
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52
LMNA P02545 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
KDM4E B2RXH2 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL713887 0.78 ILK (0.65) EGFRKDRPIK3R1PIK3CAMTOR
SCHEMBL713988 0.76 ALDH1A1 (0.64) EGFRKDRMEN1KMT2APOLB
Hydrochloric Acid SCHEMBL8812502 0.76 HSD17B10 (0.69) EGFRKDRPIK3R1PIK3CAMTOR
Hydrochloric Acid SCHEMBL8933679 0.76 EGFR (0.60) EGFRKDRPIK3R1PIK3CAMTOR
SCHEMBL326633 0.74 ALDH1A1 (0.71) MEN1KMT2AALDH1A1PKMATM
SCHEMBL13212226 0.73 KMT2A (0.64) MEN1KMT2APOLBALDH1A1PKM
SCHEMBL711654 0.73 SCN1A (0.59) EGFRKDRMEN1KMT2APOLB
SCHEMBL13154425 0.73 ALDH1A1 (0.71) MEN1KMT2AALDH1A1PKMATM
Hydrochloric Acid SCHEMBL27575105 0.73 ALDH1A1 (0.69) MEN1KMT2AALDH1A1PKMATM
SCHEMBL712318 0.72 MEN1 (0.63) EGFRKDRMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A EGFR 3255/4885KDR 3270/4885PIK3R1 1889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.